Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Feature|Articles|February 3, 2026
Roundup: Every Most Favored Nation Agreement With the Trump Administration
Author(s)Luke Halpern, Associate Editor
Fact checked by: Ron Panarotti
Explore all 16 agreements struck thus far between pharmaceutical companies and the White House to adhere to most favored nation pricing for drugs sold in the United States.
Advertisement
Advertisement
Most favored nation (MFN), the approach in which a country’s drugs are priced at the lowest amount comparable to that of any other developed nation, is being rapidly adopted in the United States. The White House has sought voluntary agreements with dozens of pharmaceutical companies to ensure compliance with MFN principles and attempt to lower drug prices for American consumers. These deals could turn the pharmaceutical industry on its head.
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Advertisement
Advertisement